NCT01078961View on ClinicalTrials.gov

An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 30, 2010

Primary Completion Date

February 28, 2013

Study Completion Date

June 30, 2016

Conditions
Melanoma
Interventions
DRUG

bortezomib

Given intravenously on days 1, 8 and 15 of each 28 day cycle

DRUG

sorafenib

400mg taken orally twice a day

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Dana-Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Sponsors
All Listed Sponsors
collaborator

Dana-Farber Cancer Institute

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

collaborator

Brigham and Women's Hospital

OTHER

collaborator

Bayer

INDUSTRY

collaborator

Millennium Pharmaceuticals, Inc.

INDUSTRY

lead

Massachusetts General Hospital

OTHER